Insmed Shares Jump 18% After Arikayce Late-Stage Win Insmed (INSM) rallied ~18% on Mar 23, 2026 after a late-stage Arikayce trial reportedly met its primary endpoint; full data and regulatory plans are pending (Seeking Alpha, Mar 23, 2026).

Insmed Shares Jump 18% After Arikayce Late-Stage Win: Insmed (INSM) rallied ~18% on Mar 23, 2026 after a late-stage Arikayce trial reportedly met its primary endpoint; full data and regulatory plans are pending… 👈 Read full analysis #Insmed #Arikayce #Pharmaceuticals #ClinicalTrials #Biotech

Insmed's 2025 Financial Results Show Robust Growth and Future Prospects for BRINSUPRI Insmed has reported strong financial results for 2025, highlighting significant growth in revenues from BRINSUPRI and ARIKAYCE. The company anticipates continued expansion in 2026.

Insmed's 2025 Financial Results Show Robust Growth and Future Prospects for BRINSUPRI #United_States #Bridgewater #Insmed #ARIKAYCE #Brinsupri

Insmed to Showcase Innovative Biopharmaceutical Therapies at Upcoming Investor Conferences in 2026 Insmed Incorporated announces its participation in two major investor conferences in March 2026, showcasing its commitment to patient-focused biopharmaceutical advancements.

Insmed to Showcase Innovative Biopharmaceutical Therapies at Upcoming Investor Conferences in 2026 #United_States #biopharmaceuticals #investor_events #Bridgewater #Insmed

Medicare still denying the medication that my mom's pulmonologist perscribed to ... help her breathe. #brinsupri is the only medication that can treat her condition, but #medicare and #humana would rather she die. Maybe #Insmed can help.

Insmed to Showcase Exciting Advances in PAH Treatment at the PVRI 2026 Congress Insmed will present significant findings on treprostinil palmitil inhalation powder at the PVRI 2026 Congress, marking an important step in PAH research.

Insmed to Showcase Exciting Advances in PAH Treatment at the PVRI 2026 Congress #USA #Bridgewater #Insmed #PAH #TPIP

Insmed Releases Business Update and Future Outlook at J.P. Morgan Healthcare Conference Insmed presented significant revenue growth and future plans for their drug portfolio during the J.P. Morgan Healthcare Conference.

Insmed Releases Business Update and Future Outlook at J.P. Morgan Healthcare Conference #United_States #San_Francisco #Insmed #ARIKAYCE #Brinsupri

Insmed Set to Present Innovative Therapies at J.P. Morgan Healthcare Conference Insmed Incorporated, a biopharmaceutical company, will present groundbreaking therapies at the upcoming 44th J.P. Morgan Healthcare Conference in San Francisco.

Insmed Set to Present Innovative Therapies at J.P. Morgan Healthcare Conference #United_States #healthcare #Biopharmaceutical #Bridgewater #Insmed

Insmed Announces Significant Updates in Clinical Trials and New Acquisition Strategy Insmed Incorporated reveals key outcomes from its clinical trials for brensocatib, alongside an exciting new acquisition that promises to enhance its therapeutic offerings.

Insmed Announces Significant Updates in Clinical Trials and New Acquisition Strategy #USA #Bridgewater #Insmed #brensocatib #monoclonal_antibody

European Commission Gives Green Light to BRINSUPRI® as Breakthrough Therapy for Non-Cystic Fibrosis Bronchiectasis The European Commission has officially approved BRINSUPRI® (brensocatib) as the groundbreaking treatment for non-cystic fibrosis bronchiectasis, a first of its kind in the EU.

European Commission Gives Green Light to BRINSUPRI® as Breakthrough Therapy for Non-Cystic Fibrosis Bronchiectasis #None #Insmed #Bronchiectasis #Brinsupri

Insmed's Global Day of Good Empowers Communities Worldwide in 2025 Insmed's fourth annual Global Day of Good sees over 1,200 employees volunteering across the globe, making a significant impact in local communities by supporting health and education initiatives.

Insmed's Global Day of Good Empowers Communities Worldwide in 2025 #United_States #Community_Service #Bridgewater #Insmed #Global_Day_of_Good

Insmed to Showcase Innovations at November and December 2025 Investor Gatherings Insmed Incorporated announces its participation in key investor conferences in November and December 2025, showcasing advancements in biopharmaceuticals.

Insmed to Showcase Innovations at November and December 2025 Investor Gatherings #United_States #biopharmaceuticals #Investor_Conferences #Bridgewater #Insmed

Insmed Reports Impressive Third-Quarter 2025 Financial Results and Updates on Product Launches Insmed Incorporated shares its third-quarter 2025 financial results, highlighting significant progress in treatment approvals and revenue growth for its products.

Insmed Reports Impressive Third-Quarter 2025 Financial Results and Updates on Product Launches #United_States #Insmed #ARIKAYCE #Bridgewater,_NJ #Brinsupri

Insmed Achieves Top Spot on Science's 2025 Biopharma Employers List Insmed Incorporated has secured the number one position in Science's 2025 Top Biopharma Employers Survey, marking their fifth consecutive year at the top.

Insmed Achieves Top Spot on Science's 2025 Biopharma Employers List #USA #Biopharma #Bridgewater #Insmed #Top_Employers

CHMP backs first drug for lung disease bronchiectasis Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, and other CHMP decisions.

#bronchiectasis #respiratory #CHMP #Insmed #brensocatib #Brinsupri #noncysticfibrosisbronchiectasis #NCFB #ASPENtrial #Sanofi #Wayrilz #rilzabrutinib #immunethrombocytopenia #ITP #SanofiWinthrop #Rezurock #belumosudil #chronicgraftversushostdisease #GvHD #transplant #KadmonPharma
zurl.co/r27x2

CHMP backs first drug for lung disease bronchiectasis Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, and other CHMP decisions.

#Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, plus other CHMP decisions.

pharmaphorum.com/news/chmp-ba...

Insmed’s BRINSUPRI™ Moves Closer to EU Approval for NCFB Treatment Insmed's BRINSUPRI™ (brensocatib) could become the first approved treatment for non-cystic fibrosis bronchiectasis in the EU, pending final regulatory decisions.

Insmed’s BRINSUPRI™ Moves Closer to EU Approval for NCFB Treatment #None #Insmed #brensocatib #BRINSUPRI™

Insmed to Showcase Pioneering Phase 3 ASPEN Study Results at CHEST 2025 Insmed reveals key findings from the Phase 3 ASPEN trial on BRINSUPRI™ at CHEST 2025, focusing on efficacy for non-CF bronchiectasis.

Insmed to Showcase Pioneering Phase 3 ASPEN Study Results at CHEST 2025 #United_States #Chicago #Insmed #Brinsupri #CHEST_2025

Insmed to Showcase Key Data at ERS Congress 2025 in Amsterdam Insmed will present critical findings at the European Respiratory Society Congress 2025, focusing on innovative treatments for pulmonary diseases.

Insmed to Showcase Key Data at ERS Congress 2025 in Amsterdam #United_States #Bridgewater #Insmed #brensocatib #ERS_Congress

VytlOne and Insmed Collaborate for Brinsupri Distribution in NCFB Treatment VytlOne announces a partnership with Insmed, becoming a limited distributor for Brinsupri™, the first FDA-approved drug for bronchiectasis.

VytlOne and Insmed Collaborate for Brinsupri Distribution in NCFB Treatment #USA #Amarillo #Insmed #VytlOne #Brinsupri

Insmed gets first FDA approval for bronchiectasis Insmed has claimed the distinction of getting the first FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis.

#Insmed has claimed the distinction of becoming the first company to get #FDA approval for a treatment for chronic lung disease non-cystic fibrosis #bronchiectasis (NFCB).

Insmed Announces Strong Second-Quarter 2025 Revenue Growth and Updates Clinical Trajectory Insmed's second-quarter 2025 results show a 19% growth in revenue driven by ARIKAYCE, with exciting clinical updates on brensocatib and other therapies.

Insmed Announces Strong Second-Quarter 2025 Revenue Growth and Updates Clinical Trajectory #United_States #Bridgewater #Insmed #ARIKAYCE #brensocatib

Insmed Announces $750 Million Public Stock Offering to Enhance Biopharmaceutical Development Insmed has priced a $750 million public offering of common stock to support its biopharmaceutical innovations and expansion. This funding aims to drive advanced research and commercialization efforts.

Insmed Announces $750 Million Public Stock Offering to Enhance Biopharmaceutical Development #United_States #Bridgewater #Insmed #ARIKAYCE #brensocatib

Insmed stock soars on positive Phase 2b study results Investing.com -- Shares of Insmed Incorporated (NASDAQ:INSM) surged 27% following the announcement of positive topline results from its Phase 2b study of Treprostinil Palmitil Inhalation Powder (TPIP) in patients with pulmonary arterial hypertension (PAH). The company reported that the study met its primary and all secondary efficacy endpoints, leading to investor optimism about the drug’s potential. The Bridgewater, New Jersey-based biopharmaceutical company disclosed that the study achieved a statistically significant 35% placebo-adjusted reduction from baseline in pulmonary vascular resistance, the primary endpoint. Secondary endpoints also showed favorable outcomes, including a 35.5-meter placebo-adjusted improvement in six-minute walk distance and a 60% placebo-adjusted reduction from baseline in NT-proBNP concentrations, both of which are indicators of the drug’s effectiveness. Insmed’s announcement also highlighted the tolerability of TPIP, with 75% of patients reaching the highest dose in the study without significant issues. The company plans to engage with the FDA to inform Phase 3 trial design, with studies expected to begin before the end of 2025 for PH-ILD and in early 2026 for PAH. The promising results from the Phase 2b study not only demonstrate TPIP’s potential as a once-daily therapy but also suggest its capability to become a preferred prostanoid treatment for PAH. Insmed’s commitment to advancing this treatment is evident as they prepare for the next stages of clinical trials. The positive reaction in Insmed’s stock price reflects the market’s confidence in the company’s pipeline and its ability to bring new therapies to market. Investors will likely keep a close watch on Insmed as it progresses with its Phase 3 trials and further engages with regulatory authorities. Following the release, competitors Liquidia Technologies (NASDAQ:LQDA) and United Therapeutics (NASDAQ:UTHR) Corporation fell 23.6% and 11.7%, respectively. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Insmed #StockMarket #Investing #Phase2B #Biotech

Brensocatib Demonstrates Consistent Efficacy in Diverse Patient Groups According to ASPEN Study Analysis New data from Insmed's ASPEN study confirm that brensocatib is effective and safe across different patient subgroups with non-cystic fibrosis bronchiectasis, setting a new treatment standard.

Brensocatib Demonstrates Consistent Efficacy in Diverse Patient Groups According to ASPEN Study Analysis #United_States #Bridgewater #Insmed #brensocatib #Bronchiectasis

Insmed's First-Quarter 2025 Recap: Growth and Anticipated Milestones Ahead Insmed Incorporated has reported its financial results for Q1 2025, showcasing significant revenue growth and outlining milestones for upcoming drug approvals and studies.

Insmed's First-Quarter 2025 Recap: Growth and Anticipated Milestones Ahead #United_States #Bridgewater #Insmed #ARIKAYCE #brensocatib

Insmed Incorporated (INSM): Among Billionaire George Soros’ Mid-Cap Stocks With Huge Upside Potential - Yahoo Finance Insmed Incorporated (INSM): Among Billionaire George Soros’ Mid-Cap Stocks With Huge Upside Potential  Yahoo Finance

Click Subscribe #Insmed #GeorgeSoros #MidCapStocks #Investing #FinanceNews

Insmed to Unveil Key Developments at BofA Securities 2025 Health Care Conference in Las Vegas Insmed Incorporated announces its upcoming presentation at the BofA Securities 2025 Health Care Conference in Las Vegas, showcasing its innovative therapies.

Insmed to Unveil Key Developments at BofA Securities 2025 Health Care Conference in Las Vegas #USA #Las_Vegas #Insmed #BofA_Securities #Health_Care_Conference

Promising Results of Insmed's Brensocatib for Bronchiectasis Published in NEJM The New England Journal of Medicine features results from Insmed's pivotal study on brensocatib, highlighting significant improvements for bronchiectasis patients. A groundbreaking step in treatment.

Promising Results of Insmed's Brensocatib for Bronchiectasis Published in NEJM #USA #Bridgewater #Insmed #brensocatib #Bronchiectasis

A lovely way to spend an afternoon; with Insmed and some excellent like-minded colleagues in Edinburgh #insmed #bronchiectasis

Insmed's Brensocatib Application Progresses with FDA Priority Review Insmed announces that the FDA will not convene a meeting regarding Brensocatib for bronchiectasis, with a target action date set for August 2025.

Insmed's Brensocatib Application Progresses with FDA Priority Review #United_States #FDA #Bridgewater #Insmed #brensocatib